Psychological and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome Undergoing a Low-FODMAP Diet: The Role of the Intestinal Barrier.
Adult
Diarrhea
/ physiopathology
Diet, Carbohydrate-Restricted
Disaccharides
Female
Fermentation
Gastrointestinal Tract
/ physiopathology
Humans
Inflammation
/ physiopathology
Intestinal Absorption
/ physiology
Intestinal Mucosa
/ physiopathology
Intestines
/ physiopathology
Irritable Bowel Syndrome
/ diet therapy
Male
Mental Disorders
/ epidemiology
Middle Aged
Monosaccharides
Oligosaccharides
Polymers
/ administration & dosage
Quality of Life
Severity of Illness Index
Surveys and Questionnaires
gastrointestinal symptom profile
intestinal barrier
irritable bowel syndrome
low FODMAP diet
psychological profile
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
19 Jul 2021
19 Jul 2021
Historique:
received:
20
05
2021
revised:
05
07
2021
accepted:
16
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
4
9
2021
Statut:
epublish
Résumé
A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (LFD) improves both gastrointestinal (GI) symptoms and the psychological profile of patients with irritable bowel syndrome with diarrhea (IBS-D). The effects of 12 weeks of LFD on GI symptom and psychological profiles in relation to inflammation and the involvement of the intestinal barrier were studied in twenty IBS-D patients. The IBS Severity Scoring System, the Symptom Checklist-90-Revised, the Italian version of the 36-Item Short-Form Health Survey, the IBS-Quality of Life (QoL) questionnaire, and the Psychophysiological questionnaire were administered. The GI barrier function was assessed by sugar absorption test, the serum and fecal zonulin levels, and the serum levels of intestinal fatty-acid binding protein and diamine oxidase. Interleukins (ILs) and lipopolysaccharide (LPS) serum levels were evaluated along with dysbiosis. At the end of LFD, GI symptoms, psychological state (mainly anxiety, somatization, psychoticism, and interpersonal sensitivity), and QoL significantly improved in these patients. Simultaneously, an improvement in small intestinal permeability and intestinal mucosal integrity occurred, while IL-6, Il-10, LPS, and fermentative dysbiosis significantly decreased. The LFD can modify the immune-inflammatory features and enhance intestinal permeability and mucosal integrity, thus determining a concurrent improvement in the clinical and psychological conditions.
Identifiants
pubmed: 34371976
pii: nu13072469
doi: 10.3390/nu13072469
pmc: PMC8308851
pii:
doi:
Substances chimiques
Disaccharides
0
Monosaccharides
0
Oligosaccharides
0
Polymers
0
polyol
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of Health
ID : RC 2020-2021, Prog. N° 16 (D.D.G. n. 700/2020)
Références
J Chromatogr A. 1998 Jun 5;809(1-2):246-51
pubmed: 9677718
Ann Gastroenterol. 2014;27(4):338-345
pubmed: 25330749
Nutrients. 2021 Mar 21;13(3):
pubmed: 33801020
Psychopharmacol Bull. 1973 Jan;9(1):13-28
pubmed: 4682398
Gut. 2018 Aug;67(8):1555-1557
pubmed: 28814485
Subcell Biochem. 2019;92:9-37
pubmed: 31214983
J Intern Med. 2019 Jul;286(1):32-40
pubmed: 30873652
J Dig Dis. 2016 Sep;17(9):572-581
pubmed: 27426409
Am J Physiol Gastrointest Liver Physiol. 2017 Mar 1;312(3):G171-G193
pubmed: 27908847
Gut. 2018 Feb;67(2):255-262
pubmed: 28104632
J Gastroenterol Hepatol. 2017 May;32(5):1018-1025
pubmed: 27862281
Dig Dis Sci. 1998 Feb;43(2):400-11
pubmed: 9512138
Gastroenterology. 1996 May;110(5):1395-403
pubmed: 8613043
Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):143-159
pubmed: 28096541
BMC Gastroenterol. 2021 May 22;21(1):235
pubmed: 34022802
Indian J Psychiatry. 2013 Jan;55(1):77-80
pubmed: 23439939
Chin Med J (Engl). 2019 Apr 20;132(8):889-904
pubmed: 30958430
Am J Gastroenterol. 2012 May;107(5):754-60
pubmed: 22334251
Mol Psychiatry. 2016 Jun;21(6):738-48
pubmed: 27090305
Gut Liver. 2012 Jul;6(3):305-15
pubmed: 22844557
Gut. 2019 Jun;68(6):996-1002
pubmed: 30108163
Neurogastroenterol Motil. 2020 Jan;32(1):e13730
pubmed: 31571351
Clin Ther. 2017 Mar;39(3):632-643
pubmed: 28237672
Nutrients. 2020 Jun 02;12(6):
pubmed: 32498383
Gut. 2003 Jan;52(1):91-3
pubmed: 12477767
Neurogastroenterol Motil. 2019 Feb;31(2):e13509
pubmed: 30549152
Neurogastroenterol Motil. 2014 Jul;26(7):1036-48
pubmed: 24796536
Nutr Clin Pract. 2019 Aug;34(4):623-630
pubmed: 30644587
Gastroenterology. 2007 Mar;132(3):913-20
pubmed: 17383420
J Clin Invest. 2018 Jan 2;128(1):267-280
pubmed: 29202473
Am J Physiol Gastrointest Liver Physiol. 2019 Jul 1;317(1):G17-G39
pubmed: 31125257
J Proteomics. 2021 May 30;240:104190
pubmed: 33766670
BMC Gastroenterol. 2018 Nov 6;18(1):167
pubmed: 30400824
Am J Gastroenterol. 2013 Jul;108(7):1066-74
pubmed: 23649183
J Neurogastroenterol Motil. 2011 Apr;17(2):131-9
pubmed: 21602989
Aliment Pharmacol Ther. 2016 Oct;44(7):693-703
pubmed: 27492648
Nutrients. 2020 Mar 08;12(3):
pubmed: 32182648
Gastroenterol Hepatol (N Y). 2014 Mar;10(3):164-74
pubmed: 24829543
J Behav Ther Exp Psychiatry. 1990 Mar;21(1):21-7
pubmed: 2197296
JAMA. 2015 Mar 3;313(9):949-58
pubmed: 25734736
Gastroenterology. 2002 Apr;122(4):1140-56
pubmed: 11910364
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
BMC Gastroenterol. 2021 Jan 7;21(1):23
pubmed: 33413140
World J Gastroenterol. 2019 Aug 7;25(29):3838-3841
pubmed: 31413521
Nat Rev Neurosci. 2011 Jul 13;12(8):453-66
pubmed: 21750565
Eur J Nutr. 2021 Sep;60(6):3505-3522
pubmed: 33585949
ISRN Psychiatry. 2013 Apr 27;2013:540134
pubmed: 23738219
Neuro Endocrinol Lett. 2008 Feb;29(1):117-24
pubmed: 18283240
Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
pubmed: 9146781
World J Gastroenterol. 2014 Jul 21;20(27):8886-97
pubmed: 25083061
Aliment Pharmacol Ther. 2019 Jul;50(2):132-143
pubmed: 31157418
Curr Opin Pharmacol. 2015 Dec;25:13-22
pubmed: 26426677
Gastroenterology. 2016 Feb 18;:
pubmed: 27144627